Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
[Translation] Study on the potency determination of PA9060 cream
比较PA9060乳膏与其他已上市不同效价的糖皮质激素外用制剂的血管收缩效能,初步确定PA9060乳膏的效价。
[Translation] The vasoconstrictive efficacy of PA9060 cream was compared with that of other marketed topical glucocorticoid preparations of different potencies, and the potency of PA9060 cream was preliminarily determined.
/ Not yet recruitingPhase 1 一项评价PA9060乳膏在中国健康研究参与者中的皮肤血管收缩效力及单次及多次给药的安全性及耐受性的I期临床研究
[Translation] A Phase I clinical study evaluating the skin vasoconstrictive efficacy of PA9060 cream and its safety and tolerability with single and multiple doses in participants of a Chinese health study.
(1)比较PA9060乳膏与其他已上市不同效价的糖皮质激素外用制剂的血管收缩效力,确定PA9060乳膏的效价;
(2)评估PA9060乳膏在中国健康成年参与者中单次及多次给药的安全性、耐受性;
(3)评估PA9060乳膏在中国健康成年参与者中多次给药的PK特征。
[Translation] (1) Compare the vasoconstrictive efficacy of PA9060 cream with other marketed topical corticosteroids of different potencies to determine the potency of PA9060 cream;
(2) Evaluate the safety and tolerability of PA9060 cream in single and multiple administrations in healthy adult participants in China;
(3) Evaluate the pharmacokinetic (PK) characteristics of PA9060 cream in multiple administrations in healthy adult participants in China.
100 Clinical Results associated with Los Altos Pharmaceuticals, Inc.
0 Patents (Medical) associated with Los Altos Pharmaceuticals, Inc.
100 Deals associated with Los Altos Pharmaceuticals, Inc.
100 Translational Medicine associated with Los Altos Pharmaceuticals, Inc.